Age is the primary risk factor for most cancers, but we devote far more resources to treating individual diseases than addressing the root cause.

Heartbroken that I might literally never get to try Fable/Mythos (as a biotech person all I’d managed to do with it was get stepped down to Opus every time)

tell me you haven't actually tried to use Fable for biology without saying you haven't actually tried to use Fable for biology

Anthropic really needs to come up with a better solution than blanket refusals to any and all bio inquiries. It’s getting silly.

I switched to the Moonshot models for biology about a month ago and it has done wonders for my cortisol levels Kimi K2.6 is 5% less performant than Opus 4.8 but 100% less likely to think you're a bioterrorist for asking it to summarize a published article

"Nature has a well-established presence on Instagram and YouTube; a few months ago, we also joined TikTok."

After a hiatus, glad to be back in the chair producing new episodes of @BioAgePodcast — a show that features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. For those of you who reached out to say you'd been missing the show — thanks for the encouragement and inspiration. And for those of you who haven't listened before, now's a great time to start.

If this sounds enticing to you, I’ve got a bridge in Brooklyn I’d like to sell you

We're pleased to share additional positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor — showing potential best-in-class hsCRP reduction in patients with elevated cardiovascular risk. Read the release: ir.bioagelabs.com/news-relea… Key findings from our first MAD cohort in obese participants with elevated hsCRP: • Rapid and profound reduction in hsCRP, a widely used marker of inflammatory cardiovascular risk: 86% median reduction at Day 14 • 93% of participants achieved hsCRP levels < 2 mg/L, the clinical threshold for reduced cardiovascular risk • Broad anti-inflammatory effects: Significant reductions in IL-6 and fibrinogen, key independent markers of cardiovascular risk • Well tolerated: Favorable safety profile with no dose-limiting toxicities Path forward: Full Phase 1 data, including additional multiple ascending dose (MAD) cohorts in participants with obesity and elevated hsCRP, anticipated 1H26 Phase 2a study on track to initiate 1H26, with readout anticipated by year-end Aging biology in action: Chronic inflammation is now recognized as a major driver of cardiovascular disease—on par with cholesterol—yet it remains undertreated. NLRP3 is a key driver of age-related inflammation, and BioAge's discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. With the potential to deliver injectable-like inflammation reduction in a convenient oral therapy, BGE-102 could address a significant unmet need in cardiovascular risk management and beyond. We look forward to sharing full Phase 1 results in the first half of this year!

What will it take to turn the science of aging into new medicines that benefit millions of people? BioAge CEO and co-founder @kpfortney sat down with @TIME magazine’s @dmosbergen for an in-depth conversation about why targeting the biology of aging could transform how we treat metabolic disease—and why the field is at an inflection point. The interview, published in TIME’s “Future of Living” series, covers topics including: • 🔬 BioAge’s human-first approach — With decades of health records and biological samples, we can study what's different about people who age well and work backward to find drug targets. • 💊 BGE-102, our lead NLRP3 inhibitor — Now in Phase 1 clinical trials, this once-daily oral therapy targets the chronic inflammation that drives cardiovascular risk as we age. • 🏃 Apelin and the biology of exercise — We're developing drugs that mimic the molecular benefits of physical activity, with potential to help maintain healthy body composition during aging and therapeutic weight loss. • 🤝 Why Big Pharma is leaning in — Our collaborations with Novartis and Lilly reflect growing recognition that aging biology offers a path to preventative medicines that address root causes of chronic disease. "I'm expecting a lot to happen in the next 5 to 10 years," Kristen says. "The growth in the field has been tremendous, so that really bodes well." Read the full interview: time.com/collections/future-…

Why does ‘anti-aging’ hype sometimes drown out the best aging science? Why does Hollywood keep casting life-extension seekers as villains? And how can we educate the public about what the biology of aging makes possible? Today at the 2025 Longevity Summit at @BuckInstitute, BioAge's VP-Media Chris Patil, PhD (@DoNotGoGently) is facilitating a conversation about the media narratives surrounding longevity science — and how we might tell them better. Joining Chris on the panel will be: - Zara Stone, Culture & Tech reporter at The San Francisco Standard - Keith Comito, CEO & President, Lifespan Research Institute - Gary J. Alan, Co-founder, ALSAE Foundation

One reason I've been resisting Gemini and sticking with Claude is the lack of consistent-context features like Projects. But I just had the thought that with Gemini 3 Pro under the hood and great RAG...is NotebookLM essentially Projects for Gemini?

Congratulations to the whole @bioagelabs team!

Looking forward to joining a panel on "Longevity in the Media" at the Longevity Summit next week!

The blockbuster GLP-1 drugs have revolutionized treatment of obesity and diabetes, but also have potential for unprecedented impact on overall healthspan. An editorial in @NatureBiotech asks: Could they be the first longevity medications? They won’t be the last. Beyond GLP-1s, the editorial spotlights two promising strategies for treating chronic disease by targeting molecular mechanisms involved in human aging: blocking inflammaging by inhibiting the NLRP3 inflammasome, and activating exerkine signaling by activating the apelin receptor APJ. BioAge’s pipeline covers both strategies — an APJ agonist program spanning both oral small molecules and long-acting biologics; and BGE-102, our oral brain-penetrant NLRP3 inhibitor with best-in-class potential, is currently in Phase 1 trials with initial data anticipated by year-end. We're developing therapies that target the root biology of metabolic aging to treat and prevent chronic disease — and pioneering the next generation of longevity drugs. Read the editorial: nature.com/articles/s41587-0…

.@WHO emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy.   WHO recommends that all women continue to follow advice of their doctors or health workers, who can help assess individual circumstances and recommend necessary medicines. Any medicine should be used with caution during pregnancy, especially in the first three months, and in line with advice from health professionals.   The full WHO statement: bit.ly/47YsgwI

Longevity companies (correctly) redefining all perturbations of cell state as "partial reprogramming" in response to funding trends.

jesus @airtable is your marketing team paid by the volume of email they send

Had an absolute blast moderating this panel at the Bay Area Aging Meeting! 🧬 Six brilliant minds and one big question: how do we get longevity science out of the lab and into patients' lives? As I say in the episode: hosting this podcast is an honor and a joy.